Incyte Inc. has several relevant cancer drugs in its
portfolio. Initially, Incyte will support IMPRESS with its drug Pemazyre.
Pemazyre is a targeted drug that attacks fibroblast growth
factor receptor 2 (FGFR2). The drug is currently approved for use in adults
with locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or
rearrangement. FGFR2 fusions / rearrangements are strong drivers of cancer
development. In IMPRESS-Norway we will be able to test the effect of Pemazyre
on patients with other cancers forms with similar FGFR2 alterations. We are
very pleased to include Pemazyre in our drug portfolio.
When we include new drugs, we go back and reanalyze the
molecular profile of the tumor for patients who have already been discussed at
the national molecular tumor board. If a relevant match is found, then we will
contact the treating oncologist to see if the new treatment alternative is
relevant for the patient.